Drug profile · INN
chlorprothixene
TARACTAN
chlorprothixene (TARACTAN) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — chlorprothixene
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
chlorprothixene (TARACTAN) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is chlorprothixene?
chlorprothixene (TARACTAN) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for chlorprothixene?
TARACTAN is a marketed brand name for chlorprothixene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of chlorprothixene?
chlorprothixene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.